<DOC>
	<DOCNO>NCT01690065</DOCNO>
	<brief_summary>The current standard therapy previously untreated adult chronic phase ( CP ) CML imatinib result long-term follow-up IRIS study prove imatinib CML CP reasonable therapy . ( 1 , 2 ) However , patient initially diagnose advanced CML , accelerate phase ( AP ) blastic phase ( BP ) . Various chemotherapy try find highly effective chemotherapy CML BP . ( 3-11 ) Imatinib patient advance CML also disappoint low response rate well short response duration , sudden transformation BC find even initial CML CP patient . ( 12-17 ) . Recent study show nilotinib dasatinib well imatinib term rapid response high molecular response newly diagnose CML patient . ( 18-21 ) More potent bcr-abl suppression nilotinib suppose active imatinib even patient advance CML . However , nilotinib patient imatinib-resistant -intolerant CML BP show low hematologic response major cytogenetic response . ( 22 , 23 )</brief_summary>
	<brief_title>Nilotinib-Chemotherapy CML Myeloid BP Bcr-abl ( + ) AML</brief_title>
	<detailed_description>1 . IMATINIB COMBINED WITH CHEMOTHERAPY FOR PHYLADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LYMPHOMA ( PH+ ALL ) The trial combine imatinib high-dose chemotherapy successfully result high response rate longer survival role bridge therapy allogeneic hematopoietic stem cell transplantation ( alloHSCT ) mean concurrent alternate regimen patient Philadelphia-positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) . ( 24-29 ) Current combination therapy imatinib chemotherapy become standard therapy Ph+ ALL new 2nd generation TKIs investigating . These experience may translate treatment CML BP . 2 . HIGH-DOSE DAUNORUBICIN IN ACUTE MYELOID LEUKEMIA ( AML ) INDUCTION CHEMOTHERAPY Two recently publish paper randomize trial compare standard dose daunorubicin ( 45 mg/m2 3 day ) high dose daunorubicin ( 90 mg/m2 3 day ) demonstrate improved CR rate survival high dose daunorubicin younger ( 60 year young ) old ( 60 year ) patient , respectively . ( 30 , 31 ) Therefore high-dose daunorubicin apply safely effectively treatment CML BP . 3 . NILOTINIB COMBINED WITH CHEMOTHERAPY FOR PHYLADELPHIA POSITIVE CML MYELOID BLASTIC PHASE ( MBP ) OR PHYLADELPHIA POSITIVE AML We try 2nd generation TKI , nilotinib high-dose daunorubicin induction chemotherapy combination find combination therapy improve response rate survival patient CML MBP .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Patients previouslyuntreated patient bcrabl gene rearrangement ( ( 9 ; 22 ) ) 20 % myeloid blast bone marrow and/or blood , convert CML CP/AP MBP initial imatinib treatment . 15 year old old , 65 year young Adequate performance status ( Karnofsky score 50 ) Adequate hepatic renal function ( AST , ALT , bilirubin creatinine &lt; 2.5 x upper normal limit ) . Elevation AST ALT due hepatic infiltration leukemic cell permit . Adequate cardiac function ( left ventricular ejection fraction 45 % heart scan echocardiogram ) Signed date informed consent must obtain . Patients without bcrabl gene rearrangement Acute lymphoblastic leukemia bcrabl gene rearrangement ( 9 ; 22 ) Any previous history TKIs except imatinib CML CP . Therapyrelated leukemia leukemia myelodysplastic syndrome . Patients CNS leukemia Patients primary granulocytic sarcoma without bone marrow involvement Prior chemotherapy leukemia anthracycline treatment malignancy . Hydroxyurea reduction leukemic cell burden induction chemotherapy permit . Presence significant active infection Presence uncontrolled bleed Significant cardiovascular disease include myocardial infarction within previous 6 month Cardiac dysfunction : LVEF &lt; 45 % institutional low normal range ( high value ) echocardiogram MUGA scan ; Long QT syndrome family history ; Clinically significant rest bradycardia ( &lt; 50 beats/minute ) ; QTc &gt; 450 msec ( QTcF formula ) baseline ECG . If QTcF &gt; 450 msec electrolyte abnormal , retest QTc correction electrolytes ; Myocardial infarction within 12 month ; Other clinically significant cardiac disease ( example , unstable angina , congestive heart failure , uncontrolled hypertension uncontrolled arrhythmia ) Chronic acute hepatic disease , pancreatic disease severe renal disease Severe lifethreatening medical condition Any coexist major illness organ failure Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible History congenital acquire coagulopathy unrelated malignancy Pregnancy issue : ( ) pregnant woman , ( b ) lactate woman , ( c ) reproductive woman confirm negative baseline pregnancy test ( ) man reproductive woman continue appropriate contraceptive method ( postmenopausal woman menstruation last 12 month consider nonreproductive ) Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia ) History noncompliance patient sign inform consent Hypersensitivity nilotinib experience Concurrent medication ( Gastrointestinal dysfunction significantly change absorption test drug ; Strong CYP3A4 inhibitor stop change medication start study ; Medication prolong QT interval stop change medication start study ) â€¢ The capsule contain lactose , nilotinib therefore recommend patient rare hereditary problem galactose intolerance , severe lactase deficiency glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>myeloid blastic phase</keyword>
	<keyword>bcr-abl ( + ) acute myeloid leukemia</keyword>
	<keyword>nilotinib</keyword>
</DOC>